Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Main Article Content

Diamant Thaci
University of Lübeck, Lübeck, Germany

Kenneth Gordon
Medical College of Wisconsin, Milwaukee, WI, USA

Melinda Gooderham
Probity Medical Research, Waterloo, ON, Canada

Bruce Strober
Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA,

Neil Korman
Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA,

Subhashis Banerjee
Bristol Myers Squibb, Princeton, NJ, USA

Subhashis Banerjee
Bristol Myers Squibb, Princeton, NJ, USA

Elizabeth Colston
Bristol Myers Squibb, Princeton, NJ, USA

Jonghyeon Kim
Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan

John Throup
Bristol Myers Squibb, Princeton, NJ, USA

Akimichi Morita
Bristol Myers Squibb, Princeton, NJ, USA

Keywords

Deucravacitinib, JAK inhibitor, psoriasis, integrated laboratory parameter results, phase 3 trial

Abstract

N/A

References

1. Nogueira M et al. Drugs 2020;80:341-351.

2. Burke JR et al. Sci Transl Med 2019;11:1-16.

3. Armstrong A et al. Presented at the Annual Meeting of the American Academy of Dermatology; 2021

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.37

Article Details

How to Cite
Thaci, D., Gordon , K. ., Gooderham, M., Strober , B., Korman, N., Banerjee, S., Banerjee, S., Colston, E., Kim, J., Throup, J., & Morita, A. (2021). Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 5(6), s37. https://doi.org/10.25251/skin.5.supp.37
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>